Coffey Steven R. S. 4

What Happened

• Steven R. S. Coffey, a director of Kazia Therapeutics Ltd (KZIA), was awarded 100,000 stock options on January 8, 2026. The options were granted for no consideration (no cash paid) and are derivative awards rather than an immediate purchase of shares. The exercise price is $9.10 per ADS, the options vest on January 8, 2027, and they expire on January 8, 2029.

Key Details

• Transaction date: 2026-01-08 (Form 4 filed 2026-07-08).
• Transaction type: Award/Grant of options (code A); 100,000 options granted at $0.00 grant price; exercise price $9.10 per ADS.
• Vesting/expiration: Vesting on 2027-01-08; expiration on 2029-01-08.
• Shares owned after transaction: Not reported in the provided filing.
• Footnote: Grant approved by the Remuneration Committee; the $9.10 exercise price reflects Australian tax considerations for resident participants (per footnote F1).
• Timeliness: Filing dated July 8, 2026 for a January 8, 2026 award — this is a late Form 4 filing (insiders typically must file within two business days), which reduces timely disclosure.

Context

• These are unexercised options (a compensation award). They do not represent immediate stock purchases or sales; value is realized only if the options are exercised and shares sold.
• Such grants are common as executive/director compensation; they are informational rather than a direct bullish/bearish trading signal.